Stay updated with breaking news from Bernard Malissen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Financial highlights 2022 total turnover of €18 million driven by strategic partnerships with pharmaceutical companies. €25.6 million available cash as of December 31st 2022, including
Corporate Alexis Vandier appointed new Chief Executive Officer to guide the Company through its next phase of growth Strategy focused on leveraging both the Company's clinical portfolio
The Scientific Advisory Board (SAB) combines the expertise of renowned scientific and international key-opinion leaders in the fields of immunology, immuno-oncology, inflammation and immunotherapy.